Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...

The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...